Bellicum Pharmaceuticals, Inc. - Common Stock (NASDAQ: BLCM) announces its next round of earnings this Tuesday, March 12. Here's Benzinga's advanced look at Bellicum's Q4 earnings report.
Earnings and Revenue
Bellicum EPS is expected to be around a loss of 56 cents per share, according to sell-side analysts. Sales will likely be near $1.19 million.
In the same quarter last year, Bellicum announced EPS loss of 61 cents. Bellicum's reported EPS has stacked up against analyst estimates in the past like this:
|Quarter||Q3 2018||Q2 2018||Q1 2018||Q4 2017|
Over the last 52-week period, shares are down 61.23 percent. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. Analyst estimates have adjusted higher for EPS and revenues over the past 90 days. Analysts seem to have settled on a Neutral rating with Bellicum. The strength of this rating has maintained conviction over the past three months.
Bellicum's Q4 conference call is scheduled to begin at 5:00 p.m. ET and can be accessed here: https://78449.themediaframe.com/dataconf/productusers/blcm/mediaframe/29021/indexl.html
See more from Benzinga
- Amphastar Pharmaceutical Q4 Earnings Preview
- Q4 Earnings Outlook For Pfenex
- PetIQ's Q4 Earnings Outlook
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.